Home » Stocks » Intra-Cellular Therapies

Intra-Cellular Therapies Inc. (ITCI)

Stock Price: $19.78 USD 0.43 (2.22%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed
After-hours: $19.40 -0.38 (-1.92%) Aug 13, 7:43 PM

Stock Price Chart

Key Info

Market Cap 1.33B
Revenue (ttm) 3.05M
Net Income (ttm) -186.57M
Shares Out 67.31M
EPS (ttm) -3.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $19.78
Previous Close $19.35
Change ($) 0.43
Change (%) 2.22%
Day's Open 19.35
Day's Range 19.27 - 19.89
Day's Volume 454,054
52-Week Range 6.75 - 43.56

More Stats

Market Cap 1.33B
Enterprise Value 947.29M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 67.31M
Float 59.13M
EPS (basic) -3.06
EPS (diluted) -3.08
FCF / Share -2.45
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.31M
Short Ratio 7.03
Short % of Float 8.35%
Beta 1.79
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 436.39
PB Ratio 3.36
Revenue 3.05M
Operating Income -192.10M
Net Income -186.57M
Free Cash Flow -162.89M
Net Cash 384.03M
Net Cash / Share 5.71
Gross Margin -2,919.44%
Operating Margin -6,296.95%
Profit Margin -6,115.50%
FCF Margin -5,339.35%
ROA -31.98%
ROE -58.64%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 9
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(128.77% upside)
Current: $19.78
Target: 45.25
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth---25.66%261.96%-84.17%-78.91%-12.22%-86.65%-
Gross Profit0.06-0.250.330.090.582.743.1223.36
Operating Income-154-162-103-118-106-30.99-26.27-16.4011.09
Net Income-148-155-97.77-116-105-30.69-26.87-16.5911.09
Shares Outstanding55.1954.7146.1843.2436.0728.6517.265.6111.20
Earnings Per Share-2.68-2.84-2.12-2.69-2.91-1.07-1.56-2.960.33
Operating Cash Flow-128-118-80.49-91.26-102-22.81-22.59-18.9016.20
Capital Expenditures-0.70-0.39-0.72-0.05-0.86-0.01-0.03-0.04-0.02
Free Cash Flow-129-119-81.22-91.31-103-22.82-22.62-18.9416.19
Cash & Equivalents22434846438447513037.1519.1522.89
Total Debt23.14--------
Net Cash / Debt20134846438447513037.1519.1522.89
Book Value19531845437647612131.6216.98-11.25
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Intra-Cellular Therapies Inc.
Country United States
Employees 330
CEO Sharon Mates

Stock Information

Ticker Symbol ITCI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ITCI


Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company is developing its lead drug candidate, CAPLYTA for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.